Related Experiment Videos
Clinical classification and survival in chronic lymphocyte leukemia
Tumori
|February 28, 1979
Summary
The Rai staging system accurately predicts survival in chronic lymphocytic leukemia (CLL) patients. Early-stage CLL patients demonstrated significantly longer median survival compared to advanced stages.
Area of Science:
- Oncology
- Hematology
Background:
- Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy.
- Accurate staging is crucial for predicting prognosis and guiding treatment in CLL patients.
Purpose of the Study:
- To evaluate the prognostic value of the Rai staging system for survival in a cohort of CLL patients.
- To assess the impact of disease activity, lymphocyte count, and other factors on patient survival.
Main Methods:
- Retrospective analysis of 61 consecutive CLL patients treated between 1962 and 1976.
- Classification of patients according to the Rai staging system at diagnosis.
- Correlation of clinical and laboratory parameters with patient survival.
Main Results:
- Median survival varied significantly by Rai stage: 73 months (Stage 0-I), 44 months (Stage II), and 32 months (Stage III-IV).
- Patients with "indolent" CLL had a median survival of 52 months, versus 32 months for "active" CLL.
- Lower lymphocyte counts (<30,000/mm³) were associated with longer survival (66 months vs. 41 months).
Conclusions:
- The Rai staging system is a reliable predictor of survival in chronic lymphocytic leukemia.
- Disease activity and lymphocyte count are important prognostic factors in CLL.
- Age and sex were not significant predictors of survival in this cohort.